Baseline characteristics of the paediatric patients included in the study
| Filled out questionnaires | Children with CF | Children with autoimmune disease | Postcancer treatment patients |
| N=71 | N=262 | N=101 | |
| Age, years (median (IQR)) | 15.3 (12.8–17.0) | 14.4 (11.6–16.4) | 13.6 (10.5–16.6) |
| Male sex, N (%) | 35 (49.3) | 97 (37.0) | 50 (49.5) |
| PedsQL General Fatigue Score, median (IQR) | 75.0 (54.2–87.5) | 75.0 (54.2–88.5) | 75.0 (50.0–91.7) |
| Severely fatigued, N (%) | 15 (21.1)* | 54 (20.6)* | 26 (26.7)* |
| Consented to use information in the child’s medical record | N=70 | N=245 | N=93 |
| BMI, median (IQR) | 18.4 (16.7–20.3) | 19.2 (17.0–21.9) | 19.1 (16.4–21.1) |
| Diagnosis, N (%) | 43 (61%) homozygote dF508; 26 (37%) heterozygote dF508; 1 (1%) other | 37 (15%) polyarticular JIA; 83 (34%) oligoarticular JIA; 12 (5%) systemic JIA; 31 (13%) other form of JIA; 35 (14%) immunodeficiency; 16 (7%) autoinflammatory condition; 31 (13%) systemic autoimmune disease | 32 (34%) solid tumour; 52 (56%) leukaemia/lymphoma; 9 (10%) brain tumour |
| Duration of disease status, years† | 15.3 (12.8–17.0) | 6 (3–9) | 0.4 (0.2–0.7) |
| Disease activity† | FEV1 %: 86.1±17.6 | cJADAS: 0.5 (0–4) (n=144) ESR: 4 mm/1st hr (2-7) (n=222) | All less than 1-year post-treatment |
If the data were normally distributed, the mean±SD is given; if not, the median and IQR is given.
*Based on cut-offs as defined in Nap-van der Vlist et al.2
†Disease duration: years since diagnosis until inclusion for children with JIA; years from end of treatment until inclusion for children postcancer treatment.
BMI, body mass index; CF, cystic fibrosis; cJADAS, clinical Juvenile Arthritis Disease Activity Score; ESR, erythrocyte sedimentation rate; FEV1 %, predicted percentage of forced expiratory volume in 1 s; JIA, juvenile idiopathic arthritis; NA, not applicable.